Background: The adult ART (antiretroviral therapy) programme started in Nigeria in 2002. After many years of ART in the country, the National implementation plan for the scale up of viral load testing was launched in 2016. Viral load estimation is the most important indicator of ART response. Aim: To describe viral suppression in adults on the HIV ART programme Material & methods: Viral load blood samples of 9450 adults on highly active antiretroviral therapy living with HIV from 4 states within Nigeria were analyzed for HIV RNA in Polymerase Chain Reaction laboratory of the Federal Teaching Hospital, Gombe between December 2017 and December 2019. Results: Males were 2577/9450 (27.3%) and 6873 (72.7%) females. Adults aged 26 - 45 years constituted 69.5% (6572). Viral load test was primarily routine in 96.3% (9098). ART was AZT/3TC/NVP in 52.5% (4962); TDF/3TC/EFV in 46.3% (4375). 48.3% (4568/9450) adults had received HAART for 1 - 5 years; 7.4% (699) for 6 months but <1 year; 37.6% (3551) 6 - 10 years and 6.7% (632) for >10 years. The most recent CD4 count before viral load request was ≥1000/μL in 6.5% (612) of adults; 500 - 999/μL in 38.6% (3651); 350 - 499 μL in 23.2% (2195) and <350 μL in 31.7% (2992). Viral load was ≥1000 c/ml in 22.9% (2167/9450) of adults. Viral load was >1000 c/ml in 22.8% (587/2577) males and 23.0% (1580/6873) females. Of adults aged 19 - 25 years, 28.4% (211/743) had viral load >1000 c/ml; 23.5% (1544/6572); 20.0% (294/1473); 17.8% (93/523) and 18.0% (25/139) aged 26 - 45 years, 46 - 55 years; 56 - 65 years and >65 years also had viral load >1000 c/ml (p value < 0.001) Viral load was >1000 c/ml in 26.0% (182/699) of adults on HAART for 6 months - 1 year and 21.3% (975/4568) after receiving HAART for 1 - 5 years. 24.9% (885/3551) and 19.8% (125/632) adults had viral load > 1000 c/ml after receiving HAART for 6 - 10 and >10 years respectively. (p value < 0.001) Conclusion: Over all viral suppression of 77% in our study is high but fell below the WHO threshold of 90%. ART programme in Nigeria requires strengthening.
References
[1]
World Health Organization (2017) HIV Drug Resistance Report 2017. Licence: CC BY-NC-SA 3.0 IGO, UNAIDS Global HIV and AIDS Statistics, 2020 Fact Sheet. World Health Organization, Geneva.
[2]
Nigeria HIV/AIDS Indicator and Impact Survey (2019) National Summary Sheet: Preliminary Findings.
[3]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) Country Reports 2018—Nigeria. https://www.unaids.org/en/regionscountries/countries/nigeria
[4]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemics.
[5]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2017) Ending AIDS: Progress towards the 90-90-90 Targets.
[6]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) Data 2018. UNAIDS, Geneva. www.unaids.org/en/resources/documents/2018/unaids-data-2018
[7]
World Health Organization (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization, Geneva.
[8]
World Health Organization (2006) HIV Drug Resistance. http://www.who.int/hiv/topics/drugresistance/en/
[9]
World Health Organization (2014) Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance) Concept Note. http://apps.who.int/iris/bitstream/10665/112802/1/9789241507196_eng.pdf?ua=1
[10]
World Health Organization (2016) Global Report on Early Warning Indicators of HIV Drug Resistance. http://www.who.int/hiv/pub/drugresistance/ewi-hivdr-2016/en/
[11]
World Health Organization (2015) Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Geneva. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en
[12]
Taieb, F., Madec, Y., Cournil, A. and Delaporte, E. (2017) Virological Success after 12 and 24 Months of Antiretroviral Therapy in Sub-Saharan Africa: Comparing Results of Trials, Cohorts and Cross-Sectional Studies Using a Systematic Review and Meta-Analysis. PLoS ONE, 12, e0174767. https://doi.org/10.1371/journal.pone.0174767
[13]
Barth, R.E., van der Loeff, M.F., Schuurman, R., Hoepelman, A.I. and Wensing, A.M. (2010) Virological Follow-Up of Adult Patients in Antiretroviral Treatment Programmes in Sub-Saharan Africa: A Systematic Review. The Lancet Infectious Diseases, 10, 155-166. https://doi.org/10.1016/S1473-3099(09)70328-7
[14]
Boender, T.S., Sigaloff, K.C., McMahon, J.H., Kiertiburanakul, S., Jordan, M.R., Barcarolo, J., et al. (2015) Long-Term Virological Outcomes of First Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 61, 1453-1461. https://doi.org/10.1093/cid/civ556
[15]
Federal Ministry of Health (2016) National Implementation Plan for Scale-Up of Viral Load Testing in Nigeria. Federal Ministry of Health, Nigeria.
[16]
Federal Ministry of Health (2016) National Guidelines for HIV Prevention Treatment and Care. National AIDS and STIs Control Programme. Federal Ministry of Health, Abuja.
[17]
Federal Ministry of Health (2010) National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults. Federal Ministry of Health, Abuja.
[18]
World Health Organization (2017) Global Action Plan on HIV Drug Resistance 2017-2021: 2018 Progress Report. https://www.who.int/hiv/pub/drugresistance/hivdr-action-plan-2017-2021/en/
[19]
Hamers, R.L., Schuurman, R., Sigaloff, K.C., Wallis, C.L., Kityo, C., Siwale, M., Mandaliya, K., Ive, P., Botes, M.E., Wellington, M. and Osibogun, A. (2012) Effect of Pretreatment HIV-1 Drug Resistance on Immunological, Virological, and Drug-Resistance Outcomes of First-Line Antiretroviral Treatment in Sub-Saharan Africa: A Multicenter Cohort Study. The Lancet Infectious Diseases, 12, 307-317. https://doi.org/10.1016/S1473-3099(11)70255-9
[20]
Bulage, L., Ssewanyana, I., Nankabirwa, V., Nsubuga, F., Kihembo, C., Pande, G., et al. (2017) Factors Associated with Virological Non Suppression among HIV Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infectious Diseases, 17, Article No. 326. https://doi.org/10.1186/s12879-017-2428-3
[21]
Tchouwa, G.T., Eymard-Duvernay, S., Cournil, A., Lamare, N., Serrano, L., Butel, C., et al. (2018) Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. Clinical Medicine, 1, 21-27. https://doi.org/10.1016/j.eclinm.2018.06.005
[22]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) Country Reports 2018—Kenya. https://www.unaids.org/en/regionscountries/countries/kenya
[23]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) Country Reports 2018—South Africa. https://www.unaids.org/en/regionscountries/countries/southafrica
[24]
Desta, A.A., Woldearegay, T.W., Futwi, N., Gebrehiwot, G.T., Gebru, G.G., Berhe, A.A., et al. (2020) HIV Virological Non-Suppression and Factors Associated with Non-Suppression among Adolescents and Adults on Antiretroviral Therapy in Northern Ethiopia: A Retrospective Study. BMC Infectious Diseases, 20, Article No. 4. https://doi.org/10.1186/s12879-019-4732-6
[25]
Fokam, J., Sosso, S.M., Yagai, B., Billong, S.C., Djubgang Mbadie, R.E., Kamgaing, Simo. R., et al. (2019) Viral Suppression in Adults, Adolescents and Children Receiving Antiretroviral Therapy in Cameroon: Adolescents at High Risk of Virological Failure in the Era of “Test and Treat”. AIDS Research and Therapy, 16, Article No. 36. https://doi.org/10.1186/s12981-019-0252-0
[26]
Woldesenbet, S.A., Kufa, T., Barron, P., Chirombo, B.C., Cheyip, M., Ayalew, K., et al. (2020) Viral Suppression and Factors Associated with Failure to Achieve Viral Suppression among Pregnant Women in South Africa. AIDS, 34, 589-597.
[27]
Lokpo, S.Y., Ofori-Attah, P., Ameke, L.S., Obirikorang, C., Orish, V.N., Kpene, G.E., et al. (2020) Viral Suppression and Its Associated Factors in HIV Patients on HAART: A Retrospective Study in the HO Municipality Ghana. AIDS Research and Treatment, 2020, Article ID: 9247451. https://doi.org/10.1155/2020/9247451
[28]
McMahon, J.H., Elliott, J.H., Bertagnolio, S., Kubiak, R. and Jordan, M.R. (2013) Viral Suppression after 12 Months of Antiretroviral Therapy in Low- and Middle Income Countries: A Systematic Review. Bulletin of the World Health Organization, 91, 377-385E. https://doi.org/10.2471/BLT.12.112946
[29]
Arpadi, S.M., Shiau, S., Gusmao, E.P.D. and Violari, A. (2017) Routine Viral Load Monitoring in HIV-Infected Infants and Children in Low- and Middle-Income Countries: Challenges and Opportunities. COMMENTARY. Journal of the International AIDS Society, 20, e2500. https://doi.org/10.1002/jia2.25001
[30]
Cornell, M., Schomaker, M., Garone, D.B., Giddy, J., Hoffmann, C.J., Lessells, R., et al. (2012) Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Medicine, 9, e1001304. https://doi.org/10.1371/journal.pmed.1001304
[31]
De Beaudrap, P., Thiam, M., Diouf, A., Toure-Kane, C., Ngom-Gueye, N.F., Vidal, N., et al. (2013) Risk of Virological Failure and Drug Resistance during First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal: Results from the ANRS 1215 Cohort. Journal of Acquired Immune Deficiency Syndromes, 62, 381-387. https://doi.org/10.1097/QAI.0b013e31827a2a7a
[32]
Datay, M.I., Boulle, A., Mant, D. and Yudkin, P. (2010) Associations with Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes, 54, 489-495. https://doi.org/10.1097/QAI.0b013e3181d91788
[33]
Abioye, A.I., Soipe, A.I., Salako, A.A., Odesanya, M.O., Okuneye, T.A., Abioye, A.I., et al. (2015) Are There Differences in Disease Progression and Mortality among Male and Female HIV Patients on Antiretroviral Therapy? A Meta-Analysis of Observational Cohorts. AIDS Care, 27, 1468-1486. https://doi.org/10.1080/09540121.2015.1114994
[34]
Beckham, S.W., Beyrer, C., Luckow, P., Doherty, M., Negussie, E.K. and Baral, S.D. (2016) Marked Sex Differences in All-Cause Mortality on Antiretroviral Therapy in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Journal of the International AIDS Society, 19, Article ID: 21106. https://doi.org/10.7448/IAS.19.1.21106
[35]
Penot, P., He’ma, A., Bado, G., Kabore, F., Sore, I., Sombie, D., et al. (2014) The Vulnerability of Men to Virologic Failure during Antiretroviral Therapy in a Public Routine Clinic in Burkina Faso. Journal of the International AIDS Society, 17, Article ID: 18646. https://doi.org/10.7448/IAS.17.1.18646
[36]
Novelli, S., Delobel, P., Bouchaud, O., Avettand-Fenoel, V., Fialaire, P., Cabié, A., et al. (2020) Enhanced Immunovirological Response in Women Compared to Men after Antiretroviral Therapy Initiation during Acute and Early HIV-1 Infection: Results from a Longitudinal Study in the French ANRS Primo Cohort. Journal of the International AIDS Society, 23, e25485. https://doi.org/10.1002/jia2.25485
[37]
Ayele, G., Tessema, B., Amsalu, A., Ferede, G. and Yismaw, G. (2018) Prevalence and Associated Factors of Treatment Failure among HIV/AIDS Patients on HAART Attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunology, 19, Article No. 37. https://doi.org/10.1186/s12865-018-0278-4
[38]
Yehia, B.R., Rebeiro, P., Althoff, K.N., Agwu, A.L., Horberg, M.A., Samji, H., et al. (2015) Impact of Age on Retention in Care and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes, 68, 413-419. https://doi.org/10.1097/QAI.0000000000000489
[39]
Sithole, Z., Mbizvo, E., Chonzi, P., Mungati, M., Juru, T.P., Shambira, G., et al. (2018) Virological Failure among Adolescents on ART, Harare City, 2017—A Case-Control Study. BMC Infectious Diseases, 18, Article No. 469. https://doi.org/10.1186/s12879-018-3372-6
[40]
Katz, I.T., Ryu, A.E., Onuegbu, A.G., Psaros, C., Weiser, S.D., Bangsberg, D.R., et al. (2013) Impact of HIV-Related Stigma on Treatment Adherence: Systematic Review and Meta-Synthesis. Journal of the International AIDS Society, 16, Article ID: 18640. https://doi.org/10.7448/IAS.16.3.18640
[41]
Peltzer, K. and Pengpid, S. (2013) Socioeconomic Factors in Adherence to HIV Therapy in Low- and Middle-Income Countries. Journal of Health, Population and Nutrition, 31, 150-170. https://doi.org/10.3329/jhpn.v31i2.16379
[42]
Kiweewa, F., Esber, A., Musingye, E., Reed, D., Crowell, T.A., Cham, F., et al. (2019) HIV Virologic Failure and Its Predictors among HIV-Infected Adults on Antiretroviral Therapy in the African Cohort Study. PLoS ONE, 14, e0211344. https://doi.org/10.1371/journal.pone.0211344
[43]
Bayu, B., Tariku, A., Bulti, A.B., Habitu, Y.A., Derso, T. and Teshome, D.F. (2017) Determinants of Virological Failure among Patients on Highly Active Antiretroviral Therapy in University of Gondar Referral Hospital, Northwest Ethiopia: A Case-Control Study. HIV/AIDS-Research and Palliative Care, 9, 153-159. https://doi.org/10.2147/HIV.S139516
[44]
Hailu, G.G., Hagos, D.G., Hagos, A.K., Wasihun, A.G. and Dejene, T.A. (2018) Virological and Immunological Failure of HAART and Associated Risk Factors among Adults and Adolescents in the Tigray Region of Northern Ethiopia. PLoS ONE, 13, e0196259. https://doi.org/10.1371/journal.pone.0196259
[45]
Kyaw, N.T.T., Harries, A.D., Kumar, A.M.V., Oo, M.M., Kyaw, K.W.Y., Win, T., et al. (2017) High Rate of Virological Failure and Low Rate of Switching to Second-Line Treatment among Adolescents and Adults Living with HIV on First Line ART in Myanmar, 2005-2015. PLoS ONE, 12, e0171780. https://doi.org/10.1371/journal.pone.0171780
[46]
Evans, D., Hirasen, K., Berhanu, R., Malete, G., Ive, P., Spencer, D., et al. (2018) Predictors of Switch to and Early Outcomes on Third-Line Antiretroviral Therapy at a Large Public-Sector Clinic in Johannesburg, South Africa. AIDS Research and Therapy, 15, Article No. 10. https://doi.org/10.1186/s12981-018-0196-9
[47]
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration (2019) Incidence of Switching to Second Line Antiretroviral Therapy and Associated Factors in Children with HIV: An International Cohort Collaboration. Lancet HIV, 6, E105-E115. https://doi.org/10.1016/S2352-3018(18)30319-9
[48]
Chhim, K., Mburu, G., Tuot, S., Sopha, R., Khol, V., Chhoun, P., et al. (2018) Factors Associated with Viral Non-Suppression among adolescents Living with HIV in Cambodia: A Cross-Sectional Study. AIDS Research and Therapy, 15, Article No. 20. https://doi.org/10.1186/s12981-018-0205-z
[49]
Rangoran, S., Colby, D.J., Truong, G.L., Bui, D.D., Nguyen, H.H., Tou, P.B., et al. (2016) Factors Associated with HIV Viral Load Suppression on Antiretroviral Therapy in Vietnam. Journal of Virus Eradication, 2, 94-101. https://doi.org/10.1016/S2055-6640(20)30466-0
[50]
Messou, E., Chaix, M.L., Gabillard, D., Minga, A., Losina, E., Yapo, V., et al. (2011) Association between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1-Infected Adults on Antiretroviral Therapy in Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 56, 356-364. https://doi.org/10.1097/QAI.0b013e3182084b5a
[51]
Muwonga, J., Edidi, S., Butel, C., Vidal, N., Monleau, M., Okenge, A., et al. (2011) Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. Journal of Acquired Immune Deficiency Syndromes, 57, S27-S33. https://doi.org/10.1097/QAI.0b013e31821f596c
[52]
Dagnra, A.Y., Vidal, N., Mensah, A., Patassi, A., Aho, K., Salou, M., et al. (2011) High Prevalence of HIV-1 Drug Resistance among Patients on First-Line Antiretroviral Treatment in Lomé, Togo. Journal of the International AIDS Society, 14, 30. https://doi.org/10.1186/1758-2652-14-30
[53]
Humphrey, J.M., Genberg, B.L., Keter, A., Musick, B., Apondi, E., Gardner, A., Hogan, J.W. and Wools-Kaloustian, K. (2019) Viral Suppression among Children and Their Caregivers Living with HIV in Western Kenya. Journal of the International AIDS Society, 22, e2527. https://doi.org/10.1002/jia2.25272
